Evidence map›Paper›PMID 41772230›Full record

ArticleNeurogenetics2026

Expanding the genotypic spectrum of combined oxidative phosphorylation deficiency 54.

King Lam Lai, Thomas B Smith, Reza Maroofian, Maha S Zaki, Swetha Ramadesikan, Tamara Reynolds, Daniel C Koboldt, Jesse M Hunter, Jorge Vidaurre, Mihaela Atanasova and 6 more

Abstract readCase Reports
In one paragraph

Article in Neurogenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

King Lam LaiDivision of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, M13 9PL, United Kingdom.
Thomas B SmithDivision of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, M13 9PL, United Kingdom.
Reza MaroofianDepartment of Molecular Neuroscience, UCL Queen Square Institute of Neurology, London, WC1N 3BG, United Kingdom.
Maha S ZakiClinical Genetics Department, Human Genetics and Genome Research Institute, National Research Centre, Cairo, 12311, Egypt.
Swetha RamadesikanThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA.
Tamara ReynoldsThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA.
Daniel C KoboldtThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA.
Jesse M HunterThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA.
Jorge VidaurreDivision of Pediatric Neurology, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University Wexner College of Medicine, Columbus, OH, USA.
Mihaela AtanasovaCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7FZ, United Kingdom.
Brian D MarsdenCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7FZ, United Kingdom.
Wyatt W YueFaculty of Medical Sciences, Newcastle University Biosciences Institute, Framlington Place, Newcastle upon Tyne, NE2 4HH, United Kingdom.
Henry HouldenDepartment of Molecular Neuroscience, UCL Queen Square Institute of Neurology, London, WC1N 3BG, United Kingdom.
Robert W TaylorMitochondrial Research Group, Clinical and Translational Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom.
William G NewmanDivision of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, M13 9PL, United Kingdom. william.newman@manchester.ac.uk.
Raymond T O'KeefeDivision of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, M13 9PL, United Kingdom. rokeefe@manchester.ac.uk.

Funding

Medical Research Council MR/W019027/1NIHR Manchester Biomedical Research Centre NIHR 203308Royal National Institute for the Deaf/Masonic Charitable Foundation S60_NewmanWellcome Centre for Mitochondrial Research 203105/Z/16/Z
6 · The paper itself

Abstract

Biallelic hypomorphic variants in PRORP cause the rare autosomal recessive disorder combined oxidative phosphorylation deficiency type 54 (COXPD54). COXPD54 encompasses a clinical spectrum of sensorineural hearing loss and ovarian insufficiency (Perrault syndrome) to leukodystrophy with developmental delay and epilepsy. Here, we report two new affected individuals with biallelic PRORP variants with clinical features consistent with COXPD54. One individual was homozygous for c.1505G > A p.Arg502Gln, whereas the other was compound heterozygous for c.1510C > T, p.His504Tyr and c.893C > A, p.Ser298Ter (NM_014672.4). In vitro tRNA processing assays revealed decreased mitochondrial 5′ tRNA leader cleavage by human RNase P complex with the two novel missense PRORP metallonuclease domain variants. These data provide further evidence that biallelic PRORP variants disrupt 5’ tRNA leader cleavage and are associated with a pleiotropic phenotype of COXPD54.

Indexed as

Gonadal Dysgenesis, 46,XXHearing Loss, SensorineuralGenotypeHumansOxidative PhosphorylationCOXPD54MitochondriaPerrault syndromePRORPRare diseaseRNase P complex

Identifiers

PMID41772230
PMCPMC12953478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.